**Burkholderia pseudomallei** capsular polysaccharide conjugates provide protection against acute melioidosis

Andrew E. Scott¹, Mary N. Burtnick², Margaret G. M. Stokes¹, Adam O. Whelan¹, E. Diane Williamson¹, Timothy P. Atkins¹, Joann L. Prior¹, Paul J. Brett²

¹ Defence Science and Technology Laboratory, Porton Down, Salisbury, UK.
² Department of Microbiology and Immunology, University of South Alabama, Mobile, Alabama, USA

**Correspondence**
Fax: +44 01980 614307. Tel: +44 01980 613800. E-mail: aescott2@dstl.gov.uk

**Running title**
Immunization against melioidosis
**Abstract**

*Burkholderia pseudomallei*, the etiologic agent of melioidosis, is a CDC Tier 1 Select Agent that causes severe disease in both humans and animals. Diagnosis and treatment of melioidosis can be challenging, and in the absence of optimal chemotherapeutic intervention acute disease is frequently fatal. Melioidosis is an emerging infectious disease for which no licensed vaccines currently exist. Due to the potential malicious use of *B. pseudomallei*, as well as its impact on public health in endemic regions, there is significant interest in developing vaccines for immunization against this disease. In the present study, type-A O-polysaccharide (OPS) and *manno*-heptose capsular polysaccharide (CPS) antigens were isolated from non-pathogenic, Select Agent-excluded strains of *B. pseudomallei* and covalently linked to carrier proteins. Using these conjugates (OPS2B1 and CPS2B1) it was demonstrated that, although high titer IgG responses against the OPS or CPS components of the glycoconjugates could be raised in BALB/c mice, only those animals immunized with CPS2B1 were protected against an intraperitoneal challenge of *B. pseudomallei*. Extending upon these studies, it was also demonstrated that when the mice were immunized with a combination of CPS2B1 and recombinant *B. pseudomallei* LolC, rather than with CPS2B1 or LolC individually, they exhibited higher survival rates when challenged with a lethal dose of *B. pseudomallei*. Collectively, these results suggest that CPS-based glycoconjugates are promising candidates for the development of subunit vaccines for immunization against melioidosis.

© Crown Copyright 2014. Published with the permission of the Defence Science and Technology Laboratory on behalf of the controller of HMSO.
Burkholderia pseudomallei is a Gram-negative, facultative intracellular pathogen that causes melioidosis, a serious and often fatal disease in humans and animals (1). While the incidence of melioidosis is particularly high in Southeast Asia and northern Australia, recent reports have expanded the endemic region to include India and Brazil. Sporadic cases of melioidosis have also been reported in various parts of the Caribbean, Central and South America, the Middle East and Africa (2, 3). B. pseudomallei can be isolated from environmental niches such as rice paddies, still or stagnant waters and moist soils which predominate in the tropics (4), and it is believed that these habitats are the primary reservoirs from which susceptible hosts acquire infections. Routes of infection include inhalation, ingestion and percutaneous inoculation (5).

Melioidosis has a broad clinical spectrum and may manifest as acute localized infections, acute pulmonary infections and fulminating septicemias or as chronic disease (6, 7). Remarkably, 20% of all community-acquired septicemias in northeast Thailand and 32% of community-acquired bacteremic pneumonias in northern Australia are due to B. pseudomallei infections (8, 9). Because of the non-specific presentation, the lack of rapid diagnostic tests and the intrinsic resistance of B. pseudomallei to commonly used antibiotics, diagnosis and treatment of melioidosis can be challenging. In the absence of optimal chemotherapeutic intervention, mortality rates associated with acute human melioidosis remain unacceptably high (40 - 50% in northeast Thailand and 19% in Australia (9, 10)). At present, there are no human vaccines available for immunization against this emerging infectious disease (for recent reviews see (11-13)). Due to the high risk of aerosol infection, the severe course of disease and the potential for malicious use, B. pseudomallei is currently classified as a CDC Tier 1 Select Agent.
Several studies have demonstrated that *B. pseudomallei* expresses a number of factors that are required for virulence in animal models of infection. Included amongst these are the Bsa type III secretion system, the VirAG two-component regulatory system and the cluster 1 type VI secretion system (for recent reviews see (5, 14)). Additionally, studies in our laboratories and others have shown that the O-polysaccharide (OPS) component of *B. pseudomallei* lipopolysaccharides (LPS) and the manno-heptose capsular polysaccharide (CPS) are both virulence determinants (15-17) and protective antigens (18). Consequently, these carbohydrate moieties have become important components of the various subunit vaccines that are currently being developed for immunization against melioidosis (19, 20).

Unlike other Gram-negative pathogens, *B. pseudomallei* isolates appear to express only a limited repertoire of OPS (21) and CPS antigens (16, 22). At present, the significance of these observations with regards to virulence and evasion of host immune responses remains to be fully determined. Nevertheless, these attributes bode well from a vaccine development standpoint. Relevant to the current study, a number of studies have shown that monoclonal and polyclonal antibodies specific for OPS and CPS can be used to passively immunize mice against lethal challenges of *B. pseudomallei* (18, 20, 23-26). Such findings confirm the protective capacity of these surface exposed antigens and support the rationale for exploring the use of OPS and CPS antigens to actively immunize against melioidosis.

Immunologically, antigens can be classified as either T cell-dependent (TD) or T cell-independent Type 1 or Type 2 (TI-1 or TI-2). Carbohydrates such as capsular antigens and O-polysaccharides are generally considered to be TI-2 antigens (27). Typically, high molecular weight TI-2 antigens such as capsular polysaccharides are immunogenic due to their ability to crosslink multiple surface immunoglobulin molecules present on antigen-specific B cells (28), but without the involvement of T helper (Th) cells, TI-2 antigens induce poor immunological memory, and only limited affinity maturation and isotype switching (29).
Additionally, without dosing at frequent intervals antibody levels often decline. Efforts to overcome the poor immunogenicity of many clinically relevant polysaccharides have led to the development of glycoconjugate vaccines (30, 31), a number of which are currently licensed for human use (32). Covalent linkage of polysaccharides to carrier proteins promotes Th cell involvement which improves immunological memory (33) and increases isotype switching. The affinities of the antibodies elicited by glycoconjugates may also be higher than those produced by polysaccharides alone (29).

In the present study, *B. pseudomallei* OPS- and CPS-based glycoconjugates were constructed and evaluated their immunogenic potential and protective capacities using a murine model of melioidosis. Collectively, the results suggest that CPS-based glycoconjugates are promising candidates for the development of subunit vaccines for immunization against melioidosis.

**Materials and methods**

**Strain and growth conditions**

The bacteria used in this study were *B. pseudomallei* strains K96243 (34), RR2808 (∆purM, ∆webB) (35) and RR2683 (∆purM, ∆rmlD) (19) and *E. coli* BL21 Star(DE3)(pLysS) (pCRT7/NT-TOPO-LolC) (36). *B. pseudomallei* strains RR2808 and RR2683 are derivatives of the adenine auxotroph Bp82 (37), a Select Agent excluded ∆purM derivative of strain 1026b. Strain RR2808 (CPS mutant; source of OPS) and RR2683 (OPS mutant; source of CPS) enable the production of highly purified polysaccharides without the requirement for BSL3 facilities. *B. pseudomallei* K96243 and *E. coli* BL21 were cultured in L-broth and on L-agar at 37°C. *B. pseudomallei* RR2808 and RR2683 were cultured in L-broth and on L-agar supplemented with thiamine (5µg/mL) and adenine (100µg/mL) at 37°C. Bacterial stocks were maintained at −80°C as 20% glycerol suspensions. Wild type *B. pseudomallei*
K96243 was handled at Advisory Committee for Dangerous Pathogens (ACDP) containment level 3.

For animal challenges, *B. pseudomallei* K96243 was inoculated from a glycerol stock into 100ml L-broth and incubated for 24 hours at 37°C with shaking (180 rpm). The OD<sub>590</sub> was adjusted to 0.4 (corresponding to approximately 4 x 10<sup>8</sup> CFU / ml) and diluted in L-broth to the correct concentration for challenge.

**OPS and CPS purification**

Broth in 2 L baffled Erlenmeyer flasks was inoculated with *B. pseudomallei* RR2808 or RR2683 and incubated overnight at 37°C with vigorous shaking. Cell pellets were obtained by centrifugation and extracted using a modified hot aqueous-phenol procedure (38). Purified OPS and CPS antigens were then obtained essentially as previously described (19, 39).

**Glycoconjugate synthesis**

The OPS2B1 and CPS2B1 glycoconjugates used in this study were synthesized using reductive amination chemistry as previously described (19, 39). Briefly, purified OPS or CPS samples were solubilized at 5 mg/ml in PBS and added to a small amber vials. To each ml of the solutions was added 6 mg (~30 mM) of sodium *meta*-periodate (NaIO<sub>4</sub>; Pierce). Once the crystals had dissolved by gentle agitation, the reaction mixtures were gently stirred at room temperature for 40 minutes. To remove any excess oxidizing agent, the reaction mixtures were applied to a Zeba Desalt Spin Columns (Pierce) equilibrated with PBS and the eluates collected. To facilitate conjugation of the OPS or CPS antigens to cationized bovine serum albumin (cBSA; Pierce), the activated polysaccharides were added to small amber vials. To each ml of the OPS or CPS solutions was added 0.5 ml of the carrier proteins (5 mg/ml in
PBS). After mixing by gentle agitation, 10μl aliquots of a sodium cyanoborohydride stock (1 M NaBH$_3$CN in 10 mM NaOH) were added to each ml of the conjugation mixtures and the reactions were gently stirred at room temperature for 4 days. Following this, 10μl aliquots of a sodium borohydride stock (1M NaBH$_4$ in 10mM NaOH) were added to each ml of the conjugation mixtures and the reactions were stirred for 40 minutes. The conjugate reactions were then brought to 5ml with ultrapure water, dialyzed against distilled water and then lyophilized. The resulting preparations were re-suspended in ultrapure water as 1mg/ml stocks and stored at -20°C until required for use. BCA assays were used to quantitate the protein concentrations of the glycoconjugate stocks (the remaining masses of which were assumed to be polysaccharide).

**LolC protein preparation**

LolC protein (encoded by BPSL2277 in *B. pseudomallei* K96243) was purified from *E. coli* BL21 Star(DE3)(pLysS) (pCRT7/NT-TOPO-LolC) as previously described (36). Briefly, cells were grown to mid-log phase at 37°C, induced by the addition of 1mM IPTG and cooled to 20°C for overnight incubation. Following cell disruption by sonication, LolC was loaded onto HisTrap FF columns (GE Healthcare) and eluted in buffer (40mM Tris-Cl, 750 mM NaCl, 1% glucose, 5% glycerol, pH 7.5) using imidazole in steps to 500mM. The recovered material was dialysed against PBS and protein purity assessed using SDS-PAGE and concentration determined using a BCA assay.

**SDS-PAGE and Western immunoblotting**

Glycoconjugate samples were analysed using SDS-PAGE and Western immunoblotting as previously described (19, 39). Briefly, samples solubilized in 1X SDS-PAGE sample buffer and heated to 100°C for 5 minutes prior to electrophoresis on 12% Precise gels (Pierce).
Proteins were visualized via staining with Coomassie Blue R-250. For Western immunoblot analyses, the glycoconjugate samples and controls were separated on the same 12% gels and electrophoretically transferred to nitrocellulose membranes, before hybridization to either B. pseudomallei OPS-specific mAb (Pp-PS-W) or a CPS-specific mAb (3C5).

**Animal studies**

All investigations involving animals were carried out according to the requirements of the UK Animal (Scientific Procedures) Act 1986. Studies were performed using 6 – 8 week old female BALB/c mice (Charles River) randomly allocated into cages of five upon arrival. Mice were held under a 12 hour light/dark cycle with free access to food and water and were implanted with a microchip to allow tracking of individual mice. After challenge with B. pseudomallei, animals were handled under ACDP containment level 3 conditions within a rigid-wall half-suit isolator. Mice were checked at least twice daily following challenge and clinical signs for each mouse recorded. Upon reaching pre-determined humane end-points, mice were culled via cervical dislocation.

Mice were immunized subcutaneously (s.c.) on days 0, 21 and 35 with the various immunogens. All immunogens were formulated in Alhydrogel 2% (500 μg/mouse; Brenntag) plus ODN 2006 (CpG; 20 μg/mouse; InvivoGen). The mice received 5μg per dose of OPS or CPS as a conjugate, 5μg per dose of unconjugated OPS or CPS and 10μg per dose of cBSA or LolC. Challenges with B. pseudomallei K96243 were delivered at day 70 via the intraperitoneal route (i.p.; the MLD at day 35 for B. pseudomallei K96243 via this route was calculated to be 744 CFU (unpublished)). For organ bacterial enumeration, animals were culled and organs removed. These were then mashed through 40μm sieves into PBS, serially diluted and plated onto L-agar.
Analysis of antibody responses

Approximately 0.1ml of blood was collected from the tail veins of mice two weeks after the final boost was administered. After clotting at 4°C, the serum was removed and stored at -20°C until required for use. Responses directed against the OPS, CPS or LolC antigens were assessed by ELISA essentially as previously described (40). A reading of twice background or above was considered positive and the titer was determined to be the reciprocal of the final positive dilution.

Statistical analysis

All graphs were produced using the program GraphPad PRISM V5.0. Survival data was analysed using a log rank (Mantel-Cox) test. Bacterial burden data was transformed to the logarithm of 10 and compared using a Mann-Whitney U-test. Antibody data was transformed to the logarithm of 10 and compared using a Mann-Whitney U-test.

Results

Glycoconjugate synthesis

Polysaccharide-based glycoconjugates represent a rational approach for immunizing against melioidosis. However, until recently isolating OPS and CPS antigens to develop these vaccine candidates has been hampered by the fact that B. pseudomallei is a Select Agent requiring specialized handling and containment practices. To address this issue, B. pseudomallei RR2808 and RR2683 (derivatives of the Select Agent-excluded strain Bp82, a ΔpurM derivative of 1026b) were created to enable us to produce these polysaccharides in a safer and more cost-effective manner without the requirement for BSL-3 containment (19, 35).
To facilitate the construction of the glycoconjugates described in this study, the OPS and CPS antigens purified from RR2808 and RR2683 were chemically activated with sodium periodate and covalently linked to cBSA via reductive amination to produce OPS2B1 and CPS2B1 (Figure 1A). Following conjugation, the samples were examined by SDS-PAGE. Results of these analyses demonstrated that in both instances the polysaccharides had covalently linked to the protein carriers as indicated by the shifts in molecular weights of the glycoconjugates relative to the unconjugated cBSA controls (Figure 1B). Additionally, Western immunoblotting confirmed that the structural integrity/antigenicity of the OPS and CPS moieties remained intact following chemical activation and linkage to the protein carriers based upon their reactivity with the Pp-PS-W or 3C5 mAbs (data not shown). Further analysis of the constructs revealed that OPS2B1 and CPS2B1 contained 60% OPS or 53% CPS (w/w) respectively.

**Immunogenicity of the glycoconjugates**

To compare the immunogenicity of the glycoconjugates, groups of BALB/c mice were immunized with OPS2B1 or CPS2B1. For control purposes, groups of mice were also immunized with a matching amount of antigen composed of mixed but unconjugated polysaccharide and cBSA. Two weeks after the final boost, serum was obtained from the mice and the LPS and CPS specific IgG titers were determined by ELISA (Figure 2). In both cases, the glycoconjugates induced significantly higher antigen-specific IgG titers than the unconjugated controls (p<0.0001). The titers elicited by the two glycoconjugates were similar in magnitude with an endpoint of ~1:100,000.

**Protective capacities of OPS2B1 and CPS2B1**
To assess the protective capacities of OPS2B1 and CPS2B1, mice immunized with the glycoconjugates or with adjuvant only were challenged with *B. pseudomallei* K96243 five weeks after the final boost. Since it has been previously observed that the first 24 hours of infection are critical to the eventual outcome for the mice (i.e. reduced counts, especially in the spleen, lead to a better outcome), 5 mice from each of the test and control groups were culled 24 hours after challenge to enable the enumeration of bacterial loads in lungs, livers and spleens. The remaining mice were then monitored for 21 days after challenge for signs of morbidity and mortality.

The OPS2B1-immunized mice and adjuvant controls received a challenge of approximately 4.05 x 10⁴ CFU (~54 MLDs at day 35). Twenty-four hours after challenge, CFUs in the livers from the OPS2B1-immunized mice were significantly lower than those of the controls (p=0.0119), whereas CFUs in the spleens and lungs were not (p=0.2222 and p=0.3095 respectively; Figure 3, panel A). Immunization led to an increase in the median time to death from 3.5 days for the controls to 10 days for the OPS2B1-immunized mice (Figure 3, panel B). However, by day 21 post-challenge all of the OPS2B1-immunized mice had succumbed to infection whilst only 80% of the control mice had succumbed. The survival curves of the OPS2B1 and adjuvant mice were not significantly different (p=0.8686; Figure 3B).

The CPS2B1-immunized mice and adjuvant controls received a lower challenge of approximately 1.06 x 10⁴ CFU (~14 MLDs at day 35), leading to less acute disease. By 24 hours after challenge (Figure 4, panel A), CPS2B1-immunized mice had significantly lower counts in both the spleens (p=0.0195) and livers (p=0.0317) but not the lungs (p=0.0952) compared to controls. The control mice in this study had a median time to death of 12.5 days. It was not possible however, to calculate a median time to death for the CPS2B1-immunized mice since by day 21 only 10% had succumbed to infection. The survival curves of the
CPS2B1 and adjuvant mice were significantly different (p=0.0059; Figure 4B). Based upon these studies, CPS2B1 appeared to provide superior protection in our murine model of melioidosis compared to OPS2B1. Because of this, a decision was made to further investigate the protective capacity of the CPS2B1 construct.

**Protective capacity of CPS2B1 formulated with LolC**

Optimal immunity to *B. pseudomallei* infections is likely to be complex, requiring both humoral and cellular immune responses. Since the CPS2B1 glycoconjugate would be predicted to provide protection primarily via the production of anti-CPS antibodies, further investigations were carried out to determine whether or not it would be advantageous to co-formulate the glycoconjugate with an additional protective antigen known to promote robust cellular immune responses. To facilitate these studies, the CPS2B1 glycoconjugate was mixed with *B. pseudomallei* LolC, a protein that has previously been shown to offer protection against melioidosis and is recognised by gamma interferon secreting T-cells in mice and seropositive humans from endemic areas (36, 41, 42).

For these studies, mice were immunized with a mixture of CPS2B1 and LolC, LolC alone, CPS2B1 alone or adjuvant only. Serum was obtained from the immunized mice 14 days after the final boost and anti-CPS- and anti-LolC-specific IgM and IgG titers were determined by ELISA. CPS-specific IgM and IgG titers were not significantly different between the groups immunized with the mixture of CPS2B1 and LolC or CPS2B1 alone (p=0.2431 for IgM and p=0.6445 for IgG; Figure 5, panel A). However, LolC-specific IgM and IgG titers were significantly different between the groups immunized with the mixture of CPS2B1 and LolC or LolC alone (p=0.0276 for IgM and p=0.0362 for IgG; Figure 5, panel B).
To assess the protective capacities of the various antigen formulations, immunized mice were challenged with *B. pseudomallei* K96243 five weeks after the final boost and signs of morbidity and mortality were monitored for 35 days (Figure 6, panel A). A higher challenge of approximately $8.44 \times 10^4$ CFU (113 MLDs at day 35) was used to assess the limits of protection offered by CPS2B1 alone as well as provide a higher likelihood of observing differences in protection between the mice immunized with the mixture of CPS2B1 and LolC or CPS2B1 alone. As anticipated, all of the mice immunized with the adjuvant only control succumbed to infection by day 2. The mice immunized with the various antigen formulations had survival curves that were significantly different from the control mice (Figure 6, panel B) with a corresponding increase in the median time to death (control = 2 days, LolC = 18 days, CPS2B1 = 29.5 days, CPS2B1 and LolC mixture = undefined). As shown in Figure 6A, immunization with the mixture of CPS2B1 and LolC offered the greatest protection with 70% of mice surviving the duration of the study. Although this was a significant improvement over immunization with LolC alone ($p=0.0002$), the survival curve was not significantly different from that of CPS2B1 alone ($p=0.3163$). Interestingly however, there was a difference in the clinical signs observed between the two vaccinated groups. Specifically, the surviving mice immunized with the mixture of CPS2B1 and LolC had no signs of disease throughout the study, whereas three of the five surviving mice immunized with CPS2B1 alone displayed clinical signs of disease (ruffled fur, hunched posture). At the end of the study, surviving mice ($n=7$ for the mixture of CPS2B1 and LolC; $n=5$ for CPS2B1) were culled and lungs, livers and spleens were removed for enumeration of bacterial colonisation (Figure 6, panel C). Due to the large variation in counts between the groups (particularly in the spleens), no significant differences were observed, although the geometric means were lower in the mice immunized with the mixture of CPS2B1 and LolC than in the mice immunized with CPS2B1 in all organs examined.
**Discussion**

Bacterial polysaccharides represent attractive antigens for the development of vaccines. In particular, capsular polysaccharides have been widely used to immunize against diseases caused by *Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis* and *Salmonella typhi* (32). *B. pseudomallei* OPS and CPS antigens also represent attractive candidates to develop melioidosis vaccines since they have both been identified as protective antigens in animal models using active (18) and passive immunization strategies (18, 20, 23-26). In this report, two glycoconjugates composed of OPS or CPS linked to a common carrier protein were constructed and their immunogenic potential and protective capacities evaluated in a murine model of melioidosis. This work details for the first time the reported use of OPS- or CPS-based glycoconjugates to actively immunize against melioidosis.

The two glycoconjugates described in this study were shown to contain roughly equivalent levels of polysaccharide (60% and 53% (w/w) for OPS2B1 and CPS2B1, respectively) which enabled direct comparisons between the immunogenic potentials of the constructs. Immunization of BALB/c mice with OPS2B1 and CPS2B1 induced similar levels of antigen-specific IgG with endpoint titers of approximately 1:100,000. In both cases, the titers induced following immunization with the glycoconjugates were significantly greater than the titers induced using unconjugated controls. Such findings are consistent with the ability of glycoconjugates to promote high titer antibody responses against their carbohydrate components (33).

Previous work has shown that mice actively immunized with *B. pseudomallei* or *B. thailandensis* LPS were protected against melioidosis (50% survival by day 35 post-challenge; (18, 43)). Similarly, both polyclonal and monoclonal antibodies recognising OPS have been shown to offer significant protection in experimental models of melioidosis when
administered passively (18, 20, 23-26). Thus, given the magnitude of the antibody responses raised against OPS2B1, it was surprising that the construct failed to provide protection in our challenge study. In our previous study it is possible that the endotoxic activity associated with whole LPS antigens may have acted as a more efficient adjuvant to promote protective anti-OPS responses in comparison to the Alhydrogel/CpG adjuvant used in the present study. Studies are ongoing to investigate this interesting phenomenon.

In contrast to the lack of protection offered by OPS2B1, CPS2B1 provided excellent protection against challenge with 90% of the mice surviving to day 21. Although some of the mice displayed signs of disease at this point, the survival curve was significantly different to that of the control mice. Since T-cell immunity directed against the CPS would not be expected to play a large role in this challenge study, it seems reasonable to speculate that the observed protection was likely due to the presence of high titer CPS-specific antibodies. These results are consistent with previous studies demonstrating the protective capacity of CPS-specific monoclonal and polyclonal antibodies when administered passively to animals (18, 23, 25, 26).

Although the immunological basis of protection remains to be determined, it is clear from our results that CPS2B1 offers better protection than OPS2B1 in our animal model. It is worth noting that the challenge dose of *B. pseudomallei* used for the CPS2B1 mice was slightly lower than that used for the OPS2B1 mice and that this resulted in a less acute disease in the control mice (MTTD of 12.5 days for control mice in the CPS2B1 study compared to 3.5 days for control mice in the OPS2B1 study). However, by 21 days post-challenge, survival in these groups was similar (30% and 20% respectively) and the survival curves for the mice immunized with adjuvant in these studies were not significantly different (p=0.4021). Based upon the results of these initial observations, it was decided to further investigate the protective capacity of CPS2B1 as well as determine whether or not the
protective capacity could be augmented by co-formulating with another protective antigen. It was decided to co-formulate CPS2B1 with a *B. pseudomallei* protein antigen against which T-cell mediated responses have been reported. For this, LolC was chosen since it is a known protective antigen (36) and is recognised by gamma interferon-secreting T-cells following immunization of mice with purified protein and by T-cells of seropositive humans in endemic areas (36, 41, 42).

In initial studies, 90% of mice immunized with CPS2B1 survived to day 21 post challenge which would have complicated the ability to observe any differences in protection if the glycoconjugate had been co-formulated with LolC. To address this issue, a higher challenge dose was used the duration of the 2nd challenge study was extended out to 35 days. This approach also enabled the limits of protection offered by CPS2B1 alone to be further investigated. Using the higher dose, there was 100% mortality in the control mice within 48 hours post-challenge. Immunization with LolC offered significant protection and an extended median time to death (18 days) compared to the control mice, but all mice eventually succumbed to infection before the end of the study. These data are consistent with previous reports for this antigen (36). In contrast, CPS2B1 performed significantly better than LolC with 50% of mice surviving to the end of the study. However, most of the animals displayed external signs of disease, visible organ pathology (e.g. splenic abscesses) and bacterial colonisation of their organs. It is interesting that CPS2B1, which would be predicted to stimulate protective anti-CPS humoral responses only (since cBSA is not a *B. pseudomallei* protein), resulted in greater survival in comparison to *B. pseudomallei* LolC which has the potential to elicit both protective humoral and cell-mediated responses. This supports recent findings by Silva *et al.* that suggest humoral immunity is critically important for vaccine induced protection against acute disease (44).
Immunization of the mice with the mixture of CPS2B1 and LolC appeared to have an additive effect and provided the highest level of protection in this study (70% of mice surviving to 35 days). While protection afforded by the combination was significantly improved compared to LolC-immunized mice, it was not in comparison to CPS2B1-immunized mice. Importantly, however, the surviving CPS2B1 and LolC mixture mice did not display clinical signs of disease throughout the study whereas three of the surviving CPS2B1 mice displayed signs of disease and would likely have succumbed to infection if the study had been extended. Based upon these findings, it appears that immunization with the mixture of CPS2B1 and LolC provided the greatest degree of protection as measured by survival and decreased signs of clinical disease in the surviving mice. The specific mechanisms underlying this protection have not yet been elucidated. It is tempting to speculate, however, that the high levels of CPS-specific antibodies protected the mice against the initial acute infection by reducing extracellular bacterial numbers, whereas LolC-specific cell mediated responses were important for control of intracellular bacteria later in infection. This possibility is in line with previous data suggesting both antibody- and cell-mediated mechanisms are important for protection (45) and is currently being investigated by our laboratories.

Collectively, the results of our current study suggest that CPS-based glycoconjugates are promising candidates for the development of subunit vaccines for immunization against melioidosis. Future studies will be required, however, to more thoroughly investigate this possibility as well as better establish immune correlates of protection for this sub-unit vaccine.

**Acknowledgements**

This work was supported by funding from the United Kingdom Ministry of Defence.
References


**Figure Legends**

**Figure 1**

Physical analysis of the B. pseudomallei OPS- and CPS-based glycoconjugates used in this study. Panel A shows the structures of the B. pseudomallei OPS and CPS antigens used to
construct the OPS2B1 and CPS2B1 glycoconjugates. SDS-PAGE and Coomassie Blue staining was used to confirm the covalent linkage of the OPS and CPS antigens to cBSA (panel B). The OPS + cBSA and CPS + cBSA lanes represent un-conjugated controls. Lanes were loaded with equal amounts of protein and carbohydrate to facilitate direct comparisons. Unconjugated cBSA is indicated by the black arrowheads.

**Figure 2**

Characterization of murine immune responses against OPS2B1 and CPS2B1. Mice were immunized via the s.c. route on days 0, 21 and 35 with the various immunogens in Alhydrogel/CpG. Serum was obtained from mice 14 days after the final boost and titers of IgG specific for *B. pseudomallei* LPS (panel A) or CPS (panel B) was determined by ELISA. Individual symbols represent a single immunized mouse. The horizontal black lines represent the geometric means for each group (n=15 for OPS2B1 group; n=14 for CPS2B1 group; n=14 for unconjugated control groups). Significance at the 95% confidence level was determined using a Mann-Whitney U-test.

**Figure 3**

Protective capacity of OPS2B1. Mice (n=15 mice per group) were immunized via the s.c. route on days 0, 21 and 35 with Alhydrogel/CpG alone (▲) or OPS2B1 formulated with Alhydrogel/CpG (Δ). Five weeks after the final boost, mice were challenged i.p. with 4.05 x 10⁴ CFU of *B. pseudomallei* K96243. Twenty-four hours after challenge, five mice from each group were culled, organs were removed and bacterial burdens determined (panel A). The remaining ten mice from each group were monitored until day 21 post-challenge and survival plotted (panel B). The horizontal black lines in panel A represent the geometric mean for each group. Significance at the 95% confidence limit for organ bacterial counts was
determined using a Mann-Whitney U-test and for survival using a Log-rank (Mantel-Cox) test and is indicated on the figure (NS = not significant).

**Figure 4**

Protective capacity of CPS2B1. Mice (n=15 mice per group) were immunized via the s.c. route on days 0, 21 and 35 with Alhydrogel/CpG alone (▲) or CPS2B1 formulated with Alhydrogel/CpG (Δ). Five weeks after the final boost, mice were challenged i.p. with 1.06 x 10^4 CFU of *B. pseudomallei* K96243. Twenty-four hours after challenge, five mice from each group were culled, organs were removed and bacterial burdens determined (panel A). The remaining ten mice from each group were monitored until day 21 post-challenge and survival plotted (panel B). The horizontal black lines in panel A represent the geometric mean for each group. Significance at the 95% confidence limit for organ bacterial counts was determined using a Mann-Whitney U-test and for survival using a Log-rank (Mantel-Cox) test and is indicated on the figure (NS = not significant).

**Figure 5**

Characterization of murine immune responses against the CPS2B1 and LolC. Mice were immunized via the s.c. route on days 0, 21 and 35 with the various immunogens. Serum was obtained from mice 14 days after the final boost with a mixture of CPS2B1 and LolC formulated with Alhydrogel/CpG (▲), CPS2B1 formulated with Alhydrogel/CpG (Δ) or LolC formulated with Alhydrogel/CpG (◊) and titers of IgM and IgG specific for *B. pseudomallei* CPS (panel A) and LolC (panel B) were determined by ELISA. Individual symbols represent a single immunized mouse (n=10 for each group) except where no response was expected (anti-CPS in LolC group and anti-LolC in CPS2B1 group) where samples were pooled by cage (n=2 for these groups). The horizontal black lines represent the
geometric means for each group. Significance at the 95% confidence level was determined using a Mann-Whitney U-test and is indicated on the figure (NS = not significant).

Figure 6

Protective capacity of CPS2B1 mixed with LolC. Mice (n=10 mice per group) were immunized via the s.c. route on days 0, 21 and 35 with a mixture of CPS2B1 and LolC formulated with Alhydrogel/CpG (●), CPS2B1 formulated with Alhydrogel/CpG (△), LolC formulated with Alhydrogel/CpG (◇) or Alhydrogel/CpG alone (▲). Five weeks after the final boost mice were challenged i.p. with 8.4 x 10^4 CFU of B. pseudomallei K96243. The mice were monitored until day 35 post-challenge and survival plotted (panel A). Significance for survival was determined using a Log-rank (Mantel-Cox) test (panel B). At the end of the study surviving mice were culled (n=7 for CPS2B1 mixed with LolC and n=5 for CPS2B1), organs were removed and bacterial burdens determined (panel C). Due to the large variation in counts between the groups (particularly in the spleens) and the limited number of survivors, significant differences could not be assessed. The horizontal black lines represent the geometric means for each group.